Acknowledgment in a ORIGEN study publication

We want to share the acknowledgment that APICES has received in ORIGEN study, which is a NSCLC retrospective study, published in the ESMO 2023 congress, in which APICES has collaborated in start-up, project management, monitoring, biostatistics, and medical writing activities.

This recognition is a great motivation for the entire APICES team to continue the commitment we bring to every project we collaborate on. APICES is very proud of the acknowledgment of our work, and we would like to thank the authors and Astrazeneca, for giving us the opportunity to appear in the acknowledgments of the publication. We also congratulate them and all the investigators on the success of their project.

This Retrospective study aims to determine the prevalence of sensitizing EGFR mutations using real-time PCR-based molecular analysis in patients with early-stage nonsquamous NSCLC with stage IA–IIIB disease, who underwent surgical resection in Spain .

You can find further information in the following link: Prevalence of EGFR gene mutations in patients with early-stage resectable non-small cell lung cancer in Spain: the ORIGEN study – Varela – Translational Lung Cancer Research